… This review focuses on the possible mechanisms through which such inhibitors may interfere
with inflammation and some of the complications that may be associated with their use. …

… CNS drug development fall below average for various reasons. These include the sheer
complexity of the brain; a propensity for CNS drugs … Coupling this challenging drug development …

… disease (CKD), is timely. It reminds the reader of the huge and often prohibitive cost of new
drug developments. … Giving the cost associated with drug development and the current global …

… PK/PD concepts are currently being implemented as early as possible in drug development
to integrate the current knowledge about mechanism of drug action and disease or system …

… Shastry BS (2006b) Role of SNPs and haplotypes in human disease and drug development.
In: Ozkan M, Heller MJ, Ferrari M (eds) Micro/nano technology in genomics and proteomics, …

… steering mechanism throughout the drug development process in order to obtain the information
relevant to be put into the drug … at the earliest phases of drug development (4). Also in …

… for intense drug discovery and development efforts… development of drugs that inhibit NF-κB
activation, and consider their potential applications in inflammatory and autoimmune diseases…

… ; bioanalytical method development and validation; disease process and therapeutic … and
refine drug development. The potential for biomarkers in medicine and drug development will …

… We conduct an annual review of the AD drug development pipeline with the intent of
understanding the progress of the field in developing new therapeutics including new agents, …

… Most recently, PK-PD modeling has also been applied in translational drug research,
particularly in interfacing drug discovery and early drug development. Within this context, PK-PD …